3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
104
Fallopian Tube Neoplasms
47
Carcinoma, Ovarian Epithelial
27
Neoplasms
12
Breast Neoplasms
7
Neoplasm Metastasis
5
Recurrence
4
Endometrial Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Peritoneal Neoplasms
3
Ovarian Cancer Recurrent
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Multiple Myeloma
2
Lung Neoplasms
2
Disease Progression
2
Colorectal Neoplasms
2
Breast Neoplasms, Male
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Vaccinia
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sezary Syndrome
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
liposomal doxorubicin
×
Gynecologic
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled